SRI-41315

立即咨询

SRI-41315

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1613509-49-1

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议
25mg	电议
50mg	电议
100mg	电议

产品介绍

SRI-41315 诱导终止密码子的长时间停顿，抑制与永久和初级人类支气管上皮细胞囊性纤维化相关的PTCs(过早终止密码子)，恢复CFTR(囊性纤维化跨膜传导调节剂)的表达和功能。SRI-41315 通过减少终止因子eRF1的丰度来抑制 PTCs。SRI-41315 还增强了氨基糖苷介导的通读，导致 CFTR 活性的协同增加。

生物活性

SRI-41315 induces a prolonged pause at stop codons and suppressesPTCs(premature termination codons) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoringCFTR(cystic fibrosis transmembrane conductance regulator) expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factoreRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases inCFTRactivity^[1].

体外研究
(In Vitro)

SRI-41315 exhibits target cell cytotoxicity (CC50) values >50 μM in both FRT and 16BE14o- cells^[1].
SRI-41315 shows improved potency and efficacy in FRT cells that translated to 16HBE14o- cells^[1].
SRI-41315 (5 μM, 20 h) depletes eRF1 levels through a proteasome-mediated degradation pathway^[1].

Western Blot Analysis^[1]

Cell Line:	CFTR-G542X 16HBEge G542X cells
Concentration:	5 μM
Incubation Time:	20 h
Result:	Depleted eRF1 levels through a proteasome-mediated degradation pathway. SRI-41315-mediated eRF1 degradation was prevented by the addition of (S)-MG132 but not the neddylation inhibitor MLN4924.

分子量

357.41

性状

Solid

Formula

C₂₂H₁₉N₃O₂

CAS 号

1613509-49-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 20.83 mg/mL(58.28 mM;Need ultrasonic)

配制储备液

浓度溶剂体积质量

1 mg

5 mg

10 mg

1 mM	2.7979 mL	13.9895 mL	27.9791 mL
5 mM	0.5596 mL	2.7979 mL	5.5958 mL
10 mM	0.2798 mL	1.3990 mL	2.7979 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。